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Abstract 
Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder of the central 
nervous system that has been thought to be a severe subtype of multiple sclerosis for a 
long time. The discovery of aquaporin-4 (AQP4) antibody as a highly specific marker 
responsible for the pathogenesis of NMO, not only has made a revolutionary pace in 
establishing a serologic distinction between the two diseases, but it has also classified 
NMO as an antibody-mediated disorder. Similarly, myasthenia gravis (MG) is a well-
known antibody-mediated disorder. In this report, we describe the case of a middle-aged 
female patient who experienced definite MG with an unclear clinical picture of chronic 
demyelinating disease that initially reflected the diagnosis of MS, but further imaging 
and paraclinical workup (e.g. positive AQP4 antibody test) revealed NMO. The 
coexistence of NMO and MG is previously described. However, this is the first case with 
NMO symptoms preceding the onset of MG. Of note, the development of MG occurred 
after a 2-year period of interferon β-1b (IFN β-1b) administration. This calls the question 
to mind of whether in our case MG is induced by the administration of interferon, instead 
of an original pathogenic link between MG and NMO. In other words, 
immunomodulatory treatments can slip the immunity towards T-helper II predominant 
pathways that can trigger MG. However, if we assume that such an explanation (i.e. 
increased susceptibility to autoantibody-mediated disorders) is true, our case can be 
considered the first case of NMO who developed MG following IFN β-1b treatment. 
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Introduction 
Neuromyelitis optica (NMO or Devic’s syndrome) is an inflammatory demyelinating 
disorder of the central nervous system (CNS) that has been thought to be a severe subtype 
of multiple sclerosis (MS) for a long time. However, evidences emerging from clinical 
status, neuroimaging, and, laboratory findings would aid in distinguishing these two 
immune-mediated conditions at their developed stages [1–4]. NMO predominantly 
affects optic nerve(s) and spinal cord; although, involvement of other parts of the CNS, 
for example, brain is possible. Indeed, NMO-related brain lesions are sometimes 
undistinguishable from those pertaining to MS and, in some instances, this makes the 
diagnosis very difficult [4, 5]. During the recent decade, the discovery of aquaporin-4 
(AQP4) antibody as a highly specific marker responsible for the pathogenesis of NMO, 
not only has made a revolutionary pace in establishing serologic distinction between the 
two diseases, but it has also classified NMO as an antibody-mediated disorder [6, 7]. 
Moreover, since this discovery, the concurrence of NMO with other types of B-cell 
autoimmunities has been focused by many authors [8, 9]. On the other hand, myasthenia 
gravis (MG) is a well-known antibody-mediated disorder that specifically affects nicotinic 
acetylcholine receptors (AChR) of the muscle tissue. The clinical picture of MG mostly 
reflects muscular fatigability caused by the disruption of AChR functions and motor-end-
plate transmissions [10]. Notwithstanding the fact that the pathophysiology of NMO and 
MG are both immune and antibody mediated, the concomitancy of these two disorders is 
uncommon whereby, to date, approximately 16 cases of this condition are reported. In all 
of such reported cases, MG preceded the development of NMO and, in the majority of 
them, NMO onset was induced by the procedure of thymectomy which is a routine 
therapy for MG [11, 12]. As far as we are aware, to date, there are no reports describing 
the development of MG after initial symptoms of the chronic course of NMO. The 
purpose of this report was to illustrate the clinical and paraclinical features of a patient 
who manifested the above-mentioned condition and discuss on possible pathogenic 
mechanisms.  
Case Report 
A 40-year-old Persian woman was admitted to our department in October 2005. Her initial 
neurologic symptoms occurred at age 33, when she was diagnosed with optic neuritis (ON) of the right 
eye and paraparesia. Over the ensuing 7 years since her first symptoms, she experienced another relapse 
of ON in the left eye and also several episodes of paresthesia and paraparesia. Neurologic examination 
revealed mild spastic paraplegia and bilateral optic atrophy. Her 48-year-old sister has definite NMO 
since 8 years (several ON and myelitis episodes, spinal lesion extending from C3 to C6, and normal 
brain MRI) with a negative AQP4 antibody test. She is currently taking immunosuppressant drugs. 
Furthermore, her nephew, a 26-year-old male, was diagnosed with definite MS since 3 years. He is 
taking interferon β-1b (IFN β-1b). No other significant disorders were present in these relatives.  
Our patient’s first brain and spinal MRI in 1998 revealed four to six periventricular and only one 
small cervical plaque(s). In 2005, the second MRI series showed several periventricular plaques with 
several new T2 lesions (fig. 1), and also, the presence of the former single plaque in the cervical spine. 
At that time, with the diagnosis of clinically definite MS, she was started on IFN β-1b every other day. 
Except for another relapse of bilateral ON (in early 2006), her neurologic status reached a stable level 
and the interferon was continued for approximately 2 years until December 2007, when she exhibited 
bilateral ptosis, diplopia, weakness of masticatory muscles, and, generalized fatigability involving four 
limbs. Repetitive nerve stimulation (Jolly’s test) was employed with a Medelec Synergy system and a 
significant decremented response was observed.  Case Rep Neurol 2011;3:268–273 
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Also, Edrophonium (Tensilon) test was performed and consequent objective improvement of signs 
was prominent. Moreover, serum titers of antibody to AChR were detected at high levels using 
immunoprecipitation methods. In this respect, the diagnosis of MG was confirmed and pyridostigmine 
(180 mg/day) and azathioprine (100 mg/day) were commenced. The patient was recommended to 
undergo thymectomy, but she did not consent to the procedure due to her psychological status.  
Over the ensuing 3 years, she was free of any demyelinating relapse until she obstinately 
discontinued the entire medications for 4 months. In late June 2010, she encountered a severe 
paraplegic attack with urinary incontinence. We performed the third series of MRI workup that showed 
a large lesion in the upper cervical spine extending longitudinally in more than three vertebral segments 
(fig. 2). AQP4 antibody was tested qualitatively, using commercially available indirect 
immunofluorescence kits (Euroimmun, Luebeck, Germany) that showed positive results. In July 2010, 
our case fulfilled the revised clinical and imaging criteria for NMO [13]. Consequently, she was 
immediately started on plasmaphresis. Afterwards, mitoxantron was administered with five doses at the 
first, second, third, fifth, and eighth months (with overall dosage of 80 mg). Then, azathioprine (100 
mg/day) and low-dose prednisolone (10 mg/day) were prescribed.  
Discussion 
We described a patient who experienced definite MG during an unclear clinical picture 
of chronic demyelinating disease that firstly reflected the diagnosis of MS, but more 
paraclinical workup (e.g. AQP4 test) in later stages revealed NMO. In sum, six points are 
worth noting about this case: (1) this is the first case with NMO symptoms preceding the 
onset of MG. (2) No thymectomy was performed after the diagnosis of MG, although 
after it, NMO symptoms continued with more severity. (3) MG symptoms occurred in a 
patient receiving interferon for 2 years. (4) After a relatively long relapse-free period, 
withdrawal of immunosuppressant drugs aggravated the NMO symptoms with great 
severity. (5) Although, initial symptoms of NMO preceded the onset of MG, 
longitudinally extensive spinal cord lesion (LESCL) occurred after MG symptoms. This 
fact is in line with previous similar reports, and (6) the first and second series of MRI 
showed periventricular plaques that could simply meet diagnostic criteria for MS.  
Regarding the first and second points, as mentioned above, all of the previous studies 
concerning the concurrence of these two disorders reported the precedence of MG, and 
the majority of them acknowledged the thymectomy as the main etiologic factor that 
could alter the balance of the self-tolerance system leading to the development of another 
autoantibody-mediated disorder [11, 12]. In other words, it is generally postulated that 
adult thymus contains suppressor T cells that are mandatory to maintain the inhibition of 
self-reactive cells, and, perform a key preventive role against autoimmune diseases [11, 14, 
15]. Of note, this pathomechanism is well supported by several clinical and laboratory 
lines of evidence [12, 15]. On the contrary, Kay et al. [16] and Furukawa et al. [17] 
reported the occurrence of NMO after MG without thymectomy. These exceptional 
instances raise two possible explanations: (1) since the majority of cases developed NMO 
after thymectomy, the concurrency in these two exceptions might have accidentally 
occurred. (2) If we assume that in these two instances – instead of a mere incidence – 
there was an underlying pathomechanism, this suggests that thymectomy might not be 
the essential preceding factor for the development of NMO. In our case, the ongoing 
course of NMO does not seem to correlate with the absence of a thymectomy procedure.  
According to the third point, to date, patients with MS or hepatitis C are reported to 
develop MG during the IFN β-1b treatment [18]. The role of incidence in such sparse 
reports cannot be ruled out because, to date, IFN has been administered to many patients Case Rep Neurol 2011;3:268–273 
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with MS who did not present such an adverse condition. However, some authors tried to 
explain these conditions by adhering to the well-documented increase of autoantibodies 
in individuals treated with IFN β-1b [19, 20]. Indeed, they postulated that interferon 
treatment can slip the immunity towards T-helper II predominant pathways and thus 
raise the susceptibility to autoantibody-mediated disorders [18, 19]. If we consider such 
explanations, then the question of whether the cause of MG in our case is also related to 
interferon comes to mind, instead of an original pathogenic link between MG and NMO. 
However, if we assume that such an explanation is true, our case can be regarded as the 
first case of NMO who developed MG induced by the administration of interferon. The 
report of this condition, if repeated in the future, can provide further evidence for the 
preference of immunosuppressive versus immunomodulatory drugs in NMO patients 
[21]. Of most importance, we remind that NMO patients are reported to be at higher risks 
of other autoantibody-mediated disorders. About one third of them represent with either 
a variety of autoimmune-mediated disorders or seropositivity for different self-reactive 
antibodies [4, 8, 9]. Hence, neurologists should be cautious that immunomodulation 
might expose NMO cases to excessive risk of other autoimmunities. In this respect and 
regarding the fourth mentioned point, our case responded well to the immunosuppressive 
drugs that were prescribed to control MG before the establishment of the NMO diagnosis. 
But unfortunately, the discontinuance of treatment deprived her from potential benefits 
of immunosuppression in controlling the course of NMO that was not still confirmed at 
that stage. Moreover, due to the fact that the AQP4 antibody test is a brand new method 
that was not ordinarily available from 2004 to 2009 in our country, she could not receive 
benefit from this method at early stages. Aside from these therapeutic benefits, to indicate 
the uniqueness of our case, it seems to be important to report the AQP4 antibody titers 
before the onset of MG. However, our patient developed MG in 2007 when the test was 
not available.  
According to the fifth point, in sum, all of the studies on concomitancy of NMO and 
MG including our case reported the occurrence of LESCL after MG. This might be 
suggestive of a pathogenic nature of MG that is not related to all clinical features of NMO 
(including ON, etc.), but related to the presentation of LESCL alone. Concerning the sixth 
point, we remind the fact that AQP4 antigen is present throughout the CNS. Besides, 10% 
of NMO patients have MS-typical brain plaques as an atypical finding. This proportion 
shows a four- to five-fold increase when reported in a Japanese population [5, 22]. This 
point further highlights the value of an early AQP4 antibody test in comparison to 
imaging techniques. In conclusion, we underline the importance of distinguishing NMO 
from MS at very initial stages that is possible by the AQP4 antibody test. Such an early 
differentiation can play a pivotal role in the management of the clinical course of the 
disease. For this test, specially, cases who firstly present with ON and paraparesia (similar 
to our case) are addressed as the first-line candidates. 
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Fig. 1. The second MRI series of the brain in 2005. Axial T2-weighted (a–d) and FLAIR sections (e–g) 
show several periventricular and subcortical plaques.  
 
 
 
Fig. 2. Sagittal T2-weighted spinal MRI shows large extending lesions in the upper cervical region. 
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